[Recommendations Onco-Urology 2010: Prostate cancer].

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Progrès en urologie (Paris)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1166-7087(10)70042-7PMID 21129644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Recommendations for best practice for prostate biopsy].

  2011cited by this paper
• [Active surveillance for localized prostate cancer].

  2011cited by this paper
• Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy.

  2010cited by this paper
• Chemoprevention of prostate cancer.

  2010cited by this paper
• Management of prostate cancer recurrence after definitive radiation therapy.

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Follow‐up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?

  2010cited by this paper
• Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

  2010cited by this paper
• [The screening of prostate cancer in 2009: overview of the oncology committee of the French Urological Association].

  2010cited by this paper
• Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?

  2010cited by this paper
• Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.

  2010cited by this paper
• Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial.

  2010cited by this paper
• Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

  2010cited by this paper
• Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

  2010cited by this paper
• Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

  2010cited by this paper
• A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam

  2010cited by this paper
• Effect of dutasteride on the risk of prostate cancer.

  2010cited by this paper
• Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients.

  2010cited by this paper
• [Salvage radical prostatectomy after external radiotherapy for prostate cancer: indications, morbidity and results. Review from CCAFU prostate section].

  2010cited by this paper
• Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?

  2010cited by this paper
• Focal Laser Ablation for Localized Prostate Cancer

  2010cited by this paper
• Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer.

  2010cited by this paper
• Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

  2010cited by this paper
• Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.

  2010cited by this paper
• Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer.

  2010cited by this paper
• Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.

  2010cited by this paper
• The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.

  2010cited by this paper
• Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy

  2010cited by this paper
• Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

  2010cited by this paper
• Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years.

  2010cited by this paper
• High-intensity focused ultrasound: ready for primetime.

  2010cited by this paper
• Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.

  2010cited by this paper
• Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

  2010cited by this paper
• Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study

  2010cited by this paper
• Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.

  2010cited by this paper
• Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy.

  2010cited by this paper
• Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy.

  2010cited by this paper
• Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.

  2010cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Insignificant prostate cancer and active surveillance: from definition to clinical implications.

  2009cited by this paper
• Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

  2009cited by this paper
• Therapeutic Guidelines for the Treatment of Bone Metastasis: A Report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology

  2009cited by this paper
• Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol.

  2009cited by this paper
• Modified Gleason grading. An updated review.

  2009cited by this paper
• Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.

  2009cited by this paper
• Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

  2009cited by this paper
• Extrafascial versus interfascial nerve-sparing technique for robotic-assisted laparoscopic prostatectomy: comparison of functional outcomes and positive surgical margins characteristics.

  2009cited by this paper
• Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

  2009cited by this paper
• Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database

  2009cited by this paper
• Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot‐assisted techniques

  2009cited by this paper
• Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

  2009cited by this paper
• High‐intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure

  2009cited by this paper
• Protocol for the examination of specimens from patients with carcinoma of the prostate gland.

  2009cited by this paper
• Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

  2009cited by this paper
• Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens

  2009cited by this paper
• Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies.

  2009cited by this paper
• Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.

  2009cited by this paper
• Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.

  2009cited by this paper
• Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography

  2009cited by this paper
• Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

  2009cited by this paper
• PATHOLOGICAL DEFINITION AND DIFFICULTIES IN ASSESSING POSITIVE MARGINS IN RADICAL PROSTATECTOMY SPECIMENS

  2009cited by this paper
• Management of complications of androgen deprivation therapy in the older man.

  2009cited by this paper
• Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.

  2009cited by this paper
• Pathological outcomes of candidates for active surveillance of prostate cancer.

  2009cited by this paper
• Duration of androgen suppression in the treatment of prostate cancer.

  2009cited by this paper
• Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon.

  2009cited by this paper
• Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

  2009cited by this paper
• Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.

  2009cited by this paper
• Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings

  2009cited by this paper
• Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance

  2009cited by this paper
• Repeat prostate biopsy--when, where, and how.

  2009cited by this paper
• Pelvic lymph node dissection in prostate cancer.

  2009cited by this paper
• Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.

  2009cited by this paper
• [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].

  2009cited by this paper
• Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

  2009cited by this paper
• [Management of erectile dysfunction after radical prostatectomy].

  2009cited by this paper
• Combined androgen blockade with bicalutamide for advanced prostate cancer

  2009cited by this paper
• Role of androgen deprivation therapy for node-positive prostate cancer.

  2009cited by this paper
• Multiparametric magnetic resonance imaging in prostate cancer: present and future

  2008cited by this paper
• PCA3: a molecular urine assay for predicting prostate biopsy outcome.

  2008cited by this paper
• Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

  2008cited by this paper
• Active surveillance for the management of prostate cancer in a contemporary cohort

  2008cited by this paper
• High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

  2008cited by this paper
• The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis.

  2008cited by this paper
• Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.

  2008cited by this paper
• Does a nerve‐sparing technique or potency affect continence after open radical retropubic prostatectomy?

  2008cited by this paper
• Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

  2008cited by this paper
• [Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006 - 5/5). Prevention of incontinence and CTMH guidelines].

  2008cited by this paper
• Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation.

  2008cited by this paper
• The role of pelvic lymphadenectomy for prostate cancer--therapeutic?

  2008cited by this paper
• Initial clinical experience with real‐time transrectal ultrasonography‐magnetic resonance imaging fusion‐guided prostate biopsy

  2008cited by this paper
• Analytical And Quantitativecytology And Histology From The Volumr 30, Number 5, October 2008

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Recommendations for the reporting of prostate carcinoma: Association of Directors of Anatomic and Surgical Pathology.

  2008cited by this paper

• Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival

  2021cites this paper
• Adherence to Treatment Guidelines and Associated Survival in Older Patients with Prostate Cancer: A Prospective Multicentre Cohort Study

  2021cites this paper
• Changes in prostate cancer screening practice by blood PSA testing between 2011 and 2017, a French population-based study

  2021cites this paper
• Clinical, Histopathological, and Prognostic Characteristics of Patients with Prostate Cancer in Lubumbashi, Democratic Republic of Congo

  2020cites this paper
• Parameter identification of a model for prostate cancer treated by intermittent therapy.

  2019cites this paper
• [12-year history of radical surgery indications for the treatment of prostate cancer].

  2019cites this paper
• Cancer de prostate faible risque diagnostiqué entre 2000 et 2010 : survie sans récidive et morbi-mortalité

  2018cites this paper
• Cancer de la prostate localisé à haut risque de récidive: résultats de la prise charge

  2018cites this paper
• Prostate cancer before renal transplantation: A multicentre study.

  2017cites this paper
• Expression of fatty acid synthase and E-cadherin markers in cancer of the prostate

  2017cites this paper
• [Interest of surgical companionship during the training period of robot-assisted radical prostatectomy].

  2017cites this paper
• [Can preoperative prostate MRI before radical prostatectomy predict extracapsular extension and the side of the index lesion?].

  2016cites this paper
• Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.

  2016cites this paper
• Prostate cancer revealed by skin metastasis: a case report in black African man

  2016cites this paper
• Current practice and access to prostate MR imaging in France.

  2016cites this paper
• Analyse d'une série de 1880 biopsies prostatiques réalisées au Centre Hospitalier Universitaire de Martinique de mars 2013 à mai 2016

  2016influential citation
• Rôle des récepteurs aux oxystérols LXRs (Liver X Receptors) dans la dissémination métastatique du cancer de la prostate

  2016cites this paper
• What risk of prostate cancer led urologist to recommend prostate biopsies?

  2015cites this paper
• [Prostate cancer treated with androgen deprivation therapy: Care and monitoring in daily practice].

  2015cites this paper
• Prostate cancer: what about reproducibility of decision made at multidisciplinary team management?

  2015cites this paper
• [The PSA caught out].

  2015cites this paper
• Cellules tumorales circulantes et cancer de la prostate avancé

  2015cites this paper
• [Prostate cancer incidence and mortality trends in France from 1980 to 2011].

  2015cites this paper
• Clinical Stage Evaluation at Diagnosis of Prostate Cancer at Urology-Andrology Clinic Cnhu-Hkm Cotonou

  2015cites this paper
• Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer

  2015cites this paper
• [Use of MRI before biopsy in diagnosis of prostate cancer: Single-operator study].

  2015cites this paper
• Évaluation des déterminants de pratique du dosage des PSA par les médecins généralistes dans le dépistage du cancer de la prostate

  2015cites this paper
• [Existence of pattern 5 on radical prostatectomy: poor prognostic factor associated with a lower biochemical recurrence-free survival].

  2014cites this paper
• [Stage IV prostate cancer in Guadeloupe, a French Caribbean archipelago].

  2014cites this paper
• [Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France].

  2014cites this paper
• Surveillance active du cancer de la prostate

  2014cites this paper
• Impact des comorbidités sur la prise en charge des cancers de la prostate : du diagnostic au traitement

  2014influential citation
• DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy

  2014cites this paper
• Prostate cancer: review in 2014.

  2014cites this paper
• [Longitudinal follow-up of the IPSS within the 5 years following treatment of a localized prostate cancer: overall analysis and by type of treatment].

  2014cites this paper
• [Comparative study of histological results between resection and biopsy of the prostate].

  2014cites this paper
• [Management of rectourethral fistulas with the York Mason procedure: surgical techniques and outcomes].

  2014cites this paper
• [Head to head comparison of two currently used nomograms predicting the risk of side specific extra capsular extension to indicate nerve sparing during radical prostatectomy for treatment of prostate cancer].

  2014cites this paper
• [Neoadjuvant before surgery treatments: state of the art in prostate cancer].

  2014cites this paper
• [Functional MRI by general radiologists in prediction of side-specific extracapsular extension after radical prostatectomy: what value in daily practice?].

  2013cites this paper
• [Comparative study of radical prostatectomy versus external beam radiotherapy (75.6 Gy) combined with hormone therapy for prostate cancer of intermediate D'Amico risk classification].

  2013cites this paper
• [Prostate brachytherapy: indications and outcomes].

  2013cites this paper
• [Preoperative endorectal MRI in prostate cancer: a monocentric retrospective cohort].

  2013cites this paper
• [Prognostic impact of tumors localized at the prostatic apex].

  2013cites this paper
• [CCAFU Recommendations 2013: Prostate cancer].

  2013cites this paper
• [Corticotherapy in castration-resistant prostate cancer].

  2013cites this paper
• [Salvage radiotherapy outcomes for biochemical recurrence following radical prostatectomy among the African-Caribbean population of Guadeloupe].

  2013cites this paper
• [Critical haematuria after prostate biopsies with RIVAROXABAN. Case report].

  2013cites this paper
• [Ureteral metastasis of prostatic adenocarcinoma: case report and literature review].

  2013cites this paper
• [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

  2013cites this paper
• [The management of prostate cancer: a retrospective chart review in 808 French men undergoing biopsy].

  2013cites this paper
• [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].

  2013cites this paper
• [Hormonal treatment in prostate cancer].

  2013cites this paper
• The learning curve of transrectal ultrasound-guided prostate biopsies: implications for training programs.

  2013cites this paper
• A new sign for detection of extracapsular extension of prostatic adenocarcinoma: sum of positive sextants per lobe combining interpretation of magnetic resonance imaging and prostate biopsy results.

  2013cites this paper
• [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].

  2013cites this paper
• [Influence of plasmatic testosterone during natural history of prostate cancer: a review].

  2013cites this paper
• Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study.

  2012cites this paper
• [Could gosereline acetate induce autoimmune-like hepatitis?].

  2012cites this paper
• [Migration of pathological stage after radical prostatectomy to higher risk tumors of relapse: comparative two-center study between 2005 and 2010].

  2012cites this paper
• [Place of bilateral pulpectomy as a method of androgen suppression therapy in prostate cancer].

  2012cites this paper
• [Androgen deprivation therapy for prostate cancer and osteoporotic risk].

  2012cites this paper
• Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma

  2012cites this paper
• [Laparoscopic sentinel lymph node (SLN) dissection for clinically localized prostate carcinoma: results obtained in the first 70 patients].

  2012cites this paper
• Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur

  2012cites this paper
• [The hypofractionated radiotherapy in the treatment of the prostate cancer: radiate less to treat more].

  2012cites this paper
• [Circulating tumor cells and advanced prostate cancer].

  2012cites this paper
• [Androgen deprivation and cardiovascular risk in prostate cancer treatment].

  2012cites this paper
• Quelle prise en charge après prostatectomie totale ?

  2012cites this paper
• [Metabolic impact of androgen deprivation therapy for prostate cancer].

  2012cites this paper
• Le curage ganglionnaire dans le cancer de la prostate : une mise au point du comité de cancérologie de l’association française d’urologie

  2012influential citation
• [Status and medicolegal implications in France pT0 stage of prostate cancer: a study by the CC-AFU].

  2012cites this paper
• [Lymphadenectomy and prostate cancer: a statement of the committee of cancerology of the French Association of Urology].

  2012cites this paper
• [Radiotherapy with androgen deprivation in high-risk prostate cancer: what outcomes on a Caribbean population?].

  2012cites this paper
• [Prostatic Stromal Tumors of Uncertain Malignant Potential (STUMP): definition, pathology, prognosis and management].

  2012cites this paper
• [Magnetic resonance imaging for delineation of prostate in radiotherapy: monocentric experience and review of literature].

  2012cites this paper
• [pT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence].

  2012cites this paper
• [Diagnostic issues of prostate biopsies. Case 1. Limited adenocarcinoma].

  2012cites this paper
• [HIFU for prostate cancer in patients with a history of severe colorectal disease].

  2011cites this paper
• [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].

  2011cites this paper
• [Surveillance after prostate cancer radiotherapy].

  2011cites this paper
• [News and perspective in management of high-risk prostate cancer].

  2011cites this paper
• [Which follow-up program after radiotherapy?].

  2011cites this paper
• [Evolution of modern imaging and development of targeted prostatic biopsies for the diagnosis of prostate cancer].

  2011cites this paper
• Evaluation de la spectroscopie du proton par RMN à 3 Tesla sans antenne endorectale chez les patients présentant un cancer de prostate localisé traité par radiothérapie exclusive

  2011cites this paper
• Screening for Prostate Cancer by Digital Rectal Examination and PSA Determination in Senegal

  2011cites this paper
• [High-risk prostate cancer. Review by the Oncology Committee of the French Urology Association].

  2011cites this paper